## What is claimed is:

- 1. A platelet production promoting agent comprising a chemically modified polypeptide wherein at least one group of the amino, carboxyl, mercapto or guanidino group in the molecule of a polypeptide having human granulocyte colony stimulating activity is chemically modified with a chemical modifying agent.
- 2. The polypeptide according to 1 wherein the polypeptide having human granulocyte colony stimulating activity comprises an amino acid sequence of SEQ ID NO:1, a part of said amino acid sequence, or an amino acid sequence wherein a part of amino acids of said sequence are replaced by other amino acids.
- 3. The platelet production promoting agent comprising the polypeptide according to claim 1 or 2 wherein a chemical modifying agent of the amino, carboxyl, mercapto or guanidino group is a polyalkylene glycol derivative or styrene-maleic acid copolymer.
- 4. The platelet production promoting agent comprising the polypeptide according to claim 3 wherein the polyalkylene glycol derivative is a polyethylene glycol derivative, polypropylene glycol derivative, or derivative of polyethylene glycol-polypropylene glycol copolymer.
- $\begin{tabular}{lll} 5. & The platelet production promoter comprising the \\ & polypeptide & according & to & claim & 3 & wherein & the & chemical \\ \end{tabular}$

modifying agent of the amino group is polyalkylene glycol derivative having the formula (I):

$$R^{1}-(M)_{n}-X-R^{2}$$
 (I)

wherein  $R^1$  represents alkyl or alkanoyl group; M represents the formula:

or

wherein r and s have any variable positive integral values, which are the same or different; n has any variable positive integral values; X represents a single bond, O, NH, or S; and  $\mathbb{R}^2$  represents the formula:

$$-\langle N - \langle N \rangle$$

wherein  $\mathbb{R}^3$  represents OH, halogen, or the formula:

$$-X^{a}-(M^{a})_{na}-R^{1a}$$

wherein  $X^a$ ,  $M^a$   $R^{1a}$  and na are identical to said X, M,  $R^1$  and n, respectively, and Y represents halogen or the formula:

$$-Z-(CH_2)_p-(O)_m-W$$

wherein Z represents O, S, or NH; W represents a carboxyl group, an active derivative thereof, or the formula:

wherein  $R^4$  represents an alkyl group; and Hal represents halogen, and p has an integral value of 1 to 6; and m has a value of 0 or 1,

wherein  $W^a$  and ma are identical to said W and m, respectively; and t has an integral value of from 0 to 6, or

wherein  $Hal^{a}$ , pa and  $R^{\prime a}$  are identical to said Hal, p and  $R^{4}$ , respectively,

and derivatives of the styrene-maleic acid copolymer having the formula (II):

wherein u and v have any variable positive integral values, which are the same or different; and  $R^5$  represents a hydrogen atom, or an alkyl group.

6. The platelet production promoting agent comprising the polypeptide according to claim 3 wherein the chemical modifying agents of carboxyl groups are polyalkylene glycol derivatives having the formula (III):

$$R^{1b}-(M^b)_{nb}-NH_2 (III)$$

wherein  $M^b$ ,  $R^{1b}$  and nb are identical to said M,  $R^1$  and n, respectively.

7. The platelet production promoter comprising the polypeptide according to claim 3 wherein the chemical modifying agents of mercapto groups are polyalkylene glycol derivatives having the formula (IV):

$$R^{1c}-(M^c)_{nc}-N$$

wherein  $M^c$ ,  $R^{1c}$ , and nc are identical to said M,  $R^1$ , and n, respectively, and styrene-maleic acid copolymers having the formula (V):

$$\begin{array}{c|c} \hline \begin{array}{c|c} CH-CH_2-CH-CH \\ \hline \hline \\ CH-CH_2-CH-CH \\ \hline \\ OH \end{array} \begin{array}{c|c} CH-CH-CH \\ \hline \\ OH \end{array}$$

wherein  $R^{5a}$ , ua, and va are identical to said  $R^{5}$ , U, and V, respectively, and one of Q and R represents a carboxyl group, and the other represents the formula:

wherein pb is identical to said p.

8. The platelet production promoting agent comprising the polypeptide according to claim 3 wherein the chemical modifying agents of guanidino groups are polyalkylene glycol derivatives having the formula (VI):

$$[\mathsf{R}^{1\underline{\mathsf{d}}}\,(\mathsf{M}^{\mathsf{d}})_{n\overline{\mathsf{d}}}\,\mathsf{O}]_{q} \qquad \qquad \mathsf{COCHO} \qquad \qquad \mathsf{(VI)}$$

wherein q has a value of 1 or 2, and  $M^4$ ,  $R^{1d}$ , and nd are identical to said M,  $R^1$ , and n, respectively.

9. A platelet production promoter comprising a modified polypeptide wherein at least one of the amino groups in the molecule of the polypeptide having human granulocyte colony stimulating activity binds to a group represented by the following formula (Ia):

$$R^{1}-(OCH_{2}CH_{2})_{n}-X-R^{2a}-$$
 (Ia)

wherein  $R^1$  represents an alkyl or alkanoyl group; n has any variable positive integral value; X represents a single bond, O, NH, or S;  $R^{2a}$  represents the formula:

$$- \bigvee_{N = \bigvee_{a}}^{N^{3a}}$$

wherein  $R^{3\alpha}$  represents OH, halogen, or the formula:

$$-X^{a}-(M^{a})_{na}-R^{1a}$$

wherein  $X^a$ ,  $R^{1a}$  and na are identical to said X,  $R^1$  and n, respectively, and  $Y^a$  represents a single bond, the formula:  $-Z-(CH_2)_n-(O)_n-CO-$ 

wherein Z represents 0, S, or NH; p has an integral value of from 1 to 6; and m has a value of 0 or 1, or the formula:  $-(CO)_{ma}-(CH_2)_{r}-CO-$ 

wherein ma is identical to said m; and t has an integral value of from 0 to 6.

- 10. A method for treating a patient with decreased platelet counts comprising administering an effective amount of the chemically modified polypeptide as defined by claim 1, 2, 3, 4, 5, 6, 7, 8, or 9 to the patient.
- 11. Use of the chemically modified polypeptide as defined by claim 1, 2, 3, 4, 5, 6, 7, 8, or 9 for the production of pharmaceutical compositions which are useful for the treatment of the patients with decreased platelet counts.
- 12. Use of the chemically modified polypeptide as defined by claim 1, 2, 3, 4, 5, 6, 7, 8, or 9 for treating patients with decreased platelet counts.
- 13. A composition for treating patients with decreased platelet counts, which comprises the chemically modified polypeptide as defined by claim 1, 2, 3, 4, 5, 6, 7, 8, or 9 in the pharmaceutically acceptable dosage form with a pharmaceutically acceptable carrier.
  - 14. A chemically modified polypeptide comprising

a polypeptide having human granulocyte colony stimulating factor activity wherein at least one amino group in the molecule is substituted with a group of the formula (Ib):

$$R^{1}-(M)_{\overline{n}}\times - (N)_{\overline{n}} \times N = \begin{pmatrix} R^{3b} \\ N \\ N = \begin{pmatrix} Z-(CH_{2})_{p}-O-CO- \end{pmatrix}$$
(1b)

wherein  $R^{\rm I}$  represents an alkyl or alkanoyl group; M represents the formula:

or

$$-(OCH_2CH_2)_r-(OCH_2CH_2CH_2)_s-$$

wherein r and s have any variable positive integral values, which are the same or different, n has any variable positive integral value; X represents a single bond, O, NH, or S;  $R^{3b}$  is identical to  $R^{3a}$ ; Z represents O, S, or NH; and p has an integral value of from 1 to 6.